Azficel-T
| Clinical data | |
|---|---|
| Trade names | Laviv |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Routes of administration | Autologous intradermal injection |
| Legal status | |
| Legal status |
|
| Identifiers | |
| UNII | |
Azficel-T, sold under the brand name Laviv, is a medication for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults.[1][2][3]
It was approved for use in the United States in June 2011.[2]
References
- ^ "Laviv (Azficel-T)". U.S. Food and Drug Administration (FDA). 22 July 2017. Retrieved 1 April 2020.
- ^ a b "Autologous Fibroblasts". U.S. Food and Drug Administration (FDA). 29 June 2017. Archived from the original on 22 July 2017. Retrieved 1 April 2020.
{{cite web}}: CS1 maint: unfit URL (link) - ^ "Laviv (azficel-T) Suspension for Intradermal Injection" (PDF). Retrieved 2 April 2020.
Further reading
- Smith SR, Munavalli G, Weiss R, et al. (July 2012). "A multicenter, double-blind, placebo-controlled trial of autologous fibroblast therapy for the treatment of nasolabial fold wrinkles". Dermatol Surg. 38 (7 Pt 2): 1234–43. doi:10.1111/j.1524-4725.2012.02349.x. PMID 22409385.
External links
- "Azficel-T". Drug Information Portal. U.S. National Library of Medicine.
- "Laviv (azficel-T)". Medscape. 28 September 2019.
- Clinical trial number NCT02120781 for "Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for the Treatment of Vocal Fold Scarring and Age-Related Dysphonia" at ClinicalTrials.gov
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
 | This medical treatment–related article is a stub. You can help Wikipedia by expanding it. |